Tanreqing Capsules protect lung and gut of mice infected with influenza virus via "lung-gut axis".
10.19540/j.cnki.cjcmm.20250105.501
- Author:
Nai-Fan DUAN
1
;
Yuan-Yuan YU
2
;
Yu-Rong HE
2
;
Feng CHEN
1
;
Lin-Qiong ZHOU
1
;
Ya-Lan LI
1
;
Shi-Qi SUN
1
;
Yan XUE
1
;
Xing ZHANG
1
;
Gui-Hua XU
1
;
Yue-Juan ZHENG
3
;
Wei ZHANG
4
Author Information
1. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
2. School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
3. School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China the Yi Diseases Research Center for Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
4. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China the Yi Diseases Research Center for Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
Tanreqing Capsules;
gut microbiota;
influenza;
lung-gut axis
- MeSH:
Animals;
Drugs, Chinese Herbal/administration & dosage*;
Mice;
Lung/metabolism*;
Mice, Inbred C57BL;
Capsules;
Orthomyxoviridae Infections/virology*;
Gastrointestinal Microbiome/drug effects*;
Male;
Humans;
Female;
Influenza A virus/physiology*;
Influenza, Human/virology*
- From:
China Journal of Chinese Materia Medica
2025;50(8):2270-2281
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the mechanism of lung and gut protection by Tanreqing Capsules on the mice infected with influenza virus based on "the lung-gut axis". A total of 110 C57BL/6J mice were randomized into control group, model group, oseltamivir group, and low-and high-dose Tanreqing Capsules groups. Ten mice in each group underwent body weight protection experiments, and the remaining 12 mice underwent experiments for mechanism exploration. Mice were infected with influenza virus A/Puerto Rico/08/1934(PR8) via nasal inhalation for the modeling. The lung tissue was collected on day 3 after gavage, and the lung tissue, colon tissue, and feces were collected on day 7 after gavage for subsequent testing. The results showed that Tanreqing Capsules alleviated the body weight reduction and increased the survival rate caused by PR8 infection. Compared with model group, Tanreqing Capsules can alleviate the lung injury by reducing the lung index, alleviating inflammation and edema in the lung tissue, down-regulating viral gene expression at the late stage of infection, reducing the percentage of neutrophils, and increasing the percentage of T cells. Tanreqing Capsules relieved the gut injury by restoring the colon length, increasing intestinal lumen mucin secretion, alleviating intestinal inflammation, and reducing goblet cell destruction. The gut microbiota analysis showed that Tanreqing Capsules increased species diversity compared with model group. At the phylum level, Tanreqing Capsules significantly increased the abundance of Firmicutes and Actinobacteria, while reducing the abundance of Bacteroidota and Proteobacteria to maintain gut microbiota balance. At the genus level, Tanreqing Capsules significantly increased the abundance of unclassified＿f＿Lachnospiraceae while reducing the abundance of Bacteroides, Eubacterium, and Phocaeicola to maintain gut microbiota balance. In conclusion, Tanreqing Capsules can alleviate mouse lung and gut injury caused by influenza virus infection and restore the balance of gut microbiota. Treating influenza from the lung and gut can provide new ideas for clinical practice.
